EECP Ecosystem
📍 EECPLocator.com🏔️ EECP with Lodging🏥 Pop-Up Clinics📖 Patient Guide Free🔬 Clinical Evidence📚 Training Courses📖 EECPBook.com
Women's Health Series›01 · Fibromyalgia|02 · Autoimmune|03 · Raynaud's
Off-Label Use · Women's Health Series · Article 01

EECP for Fibromyalgia:
Microvascular Dysfunction, Pain & the Blood Flow Connection

Fibromyalgia is not just a pain condition — it is a vascular condition. Research shows that 60–80% of fibromyalgia patients have measurable microvascular dysfunction. EECP directly addresses this root cause.

~10M
Women with fibromyalgia in US
60–80%
With microvascular dysfunction
35
Sessions in a standard course
Off-Label
Use — not FDA-cleared for fibromyalgia
The Condition

Fibromyalgia Is a Vascular Problem

Fibromyalgia is characterised by widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive impairment ("fibro fog"). It affects approximately 2–4% of the population, with women accounting for 75–90% of diagnosed cases. For decades it was dismissed as a psychological condition; we now know it has measurable physiological roots.

A consistent finding in fibromyalgia research is microvascular dysfunction — impaired blood flow in the small capillaries that supply muscles, connective tissue, and the nervous system. This reduces oxygen delivery to tissues, increases local inflammation, and sensitizes pain receptors. The result is the diffuse, disproportionate pain that defines the condition.

"Microvascular dysfunction is present in 60–80% of fibromyalgia patients and correlates with pain severity. Treatments that improve peripheral blood flow represent a rational therapeutic target." — Fibromyalgia vascular research literature

How EECP Helps

Four Mechanisms Relevant to Fibromyalgia

🩸
Microvascular Perfusion
EECP increases blood flow in the smallest capillaries — the vessels most impaired in fibromyalgia. Improved oxygen delivery to muscle tissue directly reduces the ischemic component of fibromyalgia pain.
⚡
Nitric Oxide Release
Pulsatile shear stress triggers endothelial cells to release nitric oxide, the primary vasodilator. Nitric oxide deficiency is documented in fibromyalgia patients; restoring it reduces vascular tone and pain signalling.
🔥
Anti-Inflammatory Effect
EECP reduces circulating levels of inflammatory cytokines including TNF-α and IL-6 — the same inflammatory markers elevated in fibromyalgia. Reduced systemic inflammation correlates with reduced pain sensitivity.
🧠
Central Sensitization
By improving peripheral blood flow and reducing local inflammation, EECP may reduce the afferent pain signals that drive central sensitization — the neurological amplification of pain that characterises fibromyalgia.
Treatment

What to Expect from EECP for Fibromyalgia

01
Standard course
35 one-hour sessions, typically 5 days per week over 7 weeks. Some providers offer 2 sessions per day, completing the course in 18 days.
02
Timeline for improvement
Most fibromyalgia patients report improvement in fatigue and pain within the first 2–3 weeks. Full benefit is typically seen 4–6 weeks after completing the course.
03
Cost and coverage
Off-label use is generally not covered by insurance. Out-of-pocket cost is typically $3,000–$6,000 for a full course. HSA/FSA funds can be used.
04
Finding a provider
Use the EECPLocator directory and filter by "Off-label treatment" to find providers who offer EECP for fibromyalgia and other non-cardiac conditions.
Common Questions

Frequently Asked Questions

EECP is an off-label treatment for fibromyalgia with a strong physiological rationale. Fibromyalgia is associated with microvascular dysfunction and reduced tissue perfusion. EECP improves small vessel blood flow, stimulates nitric oxide release, and reduces systemic inflammation — all mechanisms relevant to fibromyalgia pain and fatigue.

Research shows that 60–80% of fibromyalgia patients have measurable microvascular dysfunction — reduced blood flow in the small capillaries that supply muscles and connective tissue. This impairs oxygen delivery, increases local inflammation, and sensitizes pain receptors. Improving microvascular perfusion is therefore a logical treatment target.

EECP for fibromyalgia is an off-label use and is generally not covered by insurance. Medicare and most commercial plans cover EECP only for its FDA-cleared cardiac indications. Costs typically range from $3,000–$6,000 for a full 35-session course. Some patients use HSA/FSA funds.

The standard course is 35 one-hour sessions, typically 5 days per week over 7 weeks. Some providers offer an accelerated schedule of 2 sessions per day, completing the full course in 18 days. Most fibromyalgia patients report improvement in fatigue and pain within the first 2–3 weeks of treatment.

Find a Provider for Fibromyalgia →

Free Patient Guide

Not ready to search for a provider?
Get the free EECP Patient Guide first.

8 modules covering what EECP is, who it helps, how to find the right provider, and what to expect — including a section on EECP for fibromyalgia and off-label vascular conditions.

No spam. Unsubscribe any time.